Compare Nexgen Energy Ltd. Common Shares (NXE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nexgen Energy Ltd. Common Shares vs State Street SPDR S&P Biotech ETF — how do they compare? Nexgen Energy Ltd. Common Shares trades at $8.76 (market cap $5.80B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Nexgen Energy Ltd. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nexgen Energy Ltd. Common Shares for 1 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| NXE | XBI | |
|---|---|---|
Market Cap | $5.80B | $10.11B |
Volume | 6,795,738 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $13.92 | $169.55 |
52-Week Low | $7.56 | $104.99 |
Typical Hold Time | 1 Days | 38 Days |
Enterprise Value | $5.55B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nexgen Energy Ltd. Common Shares
NexGen Energy develops uranium projects in Canada. Its main asset is the Rook I Project in Saskatchewan, which includes the Arrow uranium deposit.
Read more on NXE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
